Gyre Therapeutics Inc. (L9S.SG)
Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
At close: 08:04AM CEST
| Previous close | 14.20 |
| Open | 13.80 |
| Bid | 13.50 x N/A |
| Ask | 13.90 x N/A |
| Day's range | 13.80 - 13.80 |
| 52-week range | 12.40 - 15.50 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Gyre Therapeutics Reports First Quarter 2024 Earnings
Gyre Therapeutics ( NASDAQ:GYRE ) First Quarter 2024 Results Key Financial Results Revenue: US$27.2m (down 1.6% from 1Q...
GlobeNewswireGyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Phase 3 clinical trial evaluating F351 for the treatment of CHB-associated liver fibrosis in the PRC remains on track with data anticipated by early 2025 U.S. IND submission to evaluate F351 for the treatment of NASH-associated liver fibrosis expected in late 2024; Phase 2a trial expected to initiate in 2025 Acquired the rights to complementary assets relating to nintedanib through Gyre Pharmaceuticals to improve competitiveness in the PRC Cash and cash equivalents totaled $29.8 million as of Ma
Simply Wall St.Public companies are Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) biggest owners and were rewarded after market cap rose by US$137m last week
Key Insights Significant control over Gyre Therapeutics by public companies implies that the general public has more...
© 2024 Yahoo. All rights reserved.